Can we measure prior Postmenopausal Estrogen/Progestin use? The Postmenopausal Estrogen/Progestin Interventions Trial

被引:0
|
作者
Greendale, GA
James, MK
Espeland, MA
BarrettConnor, E
机构
[1] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103
[2] UNIV CALIF SAN DIEGO,SCH MED,DEPT FAMILY & PREVENT MED,LA JOLLA,CA 92093
关键词
data collection; estrogen replacement therapy; menopause; progestational hormones; randomized controlled trials; recall;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The objective of this study was to assess: 1) the accuracy of a single self-report question about postmenopausal estrogen use; and 2) the performance and repeated measures agreement of a standardized hormone use interview. Women (n = 863) in the Postmenopausal Estrogen/Progestin Interventions Trial (PEPI) completed a self-report baseline questionnaire (BQ) at enrollment and a History of Hormone Use interview (HHU) at the 3-month follow-up visit (HHU3mos). A subsample of 101 women completed a second HHU interview 3 years later (HHU3yrs). As determined by the HHU3mos, 479 (56%) of women had ever used postmenopausal estrogen and 261 (30%) had ever used postmenopausal progestin. The mean number of years since last estrogen or progestin use was 2.2 and 1.3 years, respectively. Overall, there was 95% agreement between self-reported estrogen use on the BQ and the HHU3mos (kappa = 0.91). Using the HHU3mos as the criterion standard, the BQ misclassified 2.3% of women as false positives and 6.3% as false negatives. The average duration of estrogen use in the false-negative classifications was 1.9 years (range: 1-9 years). On the HHU3mos, 39.7% of participants could not recall at least one of the specific details of estrogen use (preparation, dose, route, or starting or stopping year); similar patterns of recall were found for progestin use. Factors associated with discordant reporting of ever-use of ERT (BQ vs. HHU3mos) or incomplete reporting of estrogen/progestin use on the HHU3mos were: route of administration, recency of hormone use, duration of hormone use, and race. Age, years since menopause, education, income, and hysterectomy status were not related to discordant and/or incomplete reporting. Agreement between the HHU3mos and HHU3yrs for ever-use of estrogen was 85.2% (kappa = 0.71). in sum, a single self-report question was adequate to ascertain ever-use of postmenopausal estrogen. When a structured interview form was used, details of postmenopausal estrogen and progestin use were not well remembered. Some features of hormone use and participant characteristics were associated with completeness of recalled hormone use, which suggests the potential for differential misclassification.
引用
收藏
页码:763 / 770
页数:8
相关论文
共 50 条
  • [21] DOSE DEPENDENT EFFECTS OF POSTMENOPAUSAL ESTROGEN PROGESTIN ON COAGULATION
    GORDON, EM
    WILLIAMS, SR
    FRENCHEK, B
    MAZUR, CA
    SPEROFF, L
    CLINICAL RESEARCH, 1987, 35 (06): : A890 - A890
  • [22] Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
    Chlebowski, Rowan T.
    Kuller, Lewis H.
    Prentice, Ross L.
    Stefanick, Marcia L.
    Manson, Joann E.
    Gass, Margery
    Aragaki, Aaron K.
    Ockene, Judith K.
    Lane, Dorothy S.
    Sarto, Gloria E.
    Rajkovic, Aleksandar
    Schenken, Robert
    Hendrix, Susan L.
    Ravdin, Peter M.
    Rohan, Thomas E.
    Yasmeen, Shagufta
    Anderson, Garnet
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (06): : 573 - 587
  • [23] Breast cancer outcome and estrogen plus progestin use in postmenopausal women
    Chiebowski, R. T.
    Anderson, G. L.
    Gass, M.
    Lane, D. S.
    Aragaki, A. K.
    Kuller, L. H.
    Manson, J. E.
    Stefanick, M. L.
    Ockene, J.
    Prentice, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Estrogen plus progestin and colorectal cancer in postmenopausal women
    Chlebowski, RT
    Wactawski-Wende, J
    Ritenbaugh, C
    Hubbell, FA
    Ascensao, J
    Rodabough, RJ
    Rosenberg, CA
    Taylor, VM
    Harris, R
    Chen, C
    Adams-Campbell, LL
    White, E
    Alving, B
    Rossouw, J
    Pottern, L
    Ludlam, S
    McGowan, J
    Prentice, R
    Anderson, G
    LaCroix, A
    Patterson, R
    McTiernan, A
    Cochrane, B
    Hunt, J
    Tinker, L
    Kooperberg, C
    McIntosh, M
    Wang, CY
    Chen, C
    Bowen, D
    Kristal, A
    Stanford, J
    Urban, N
    Weiss, N
    White, E
    Shumaker, S
    Rautaharju, P
    Prineas, R
    Naughton, M
    Stein, E
    Laskarzewski, P
    Cummings, S
    Nevitt, M
    Dockrell, M
    Harnack, L
    Cammarata, F
    Lindenfelser, S
    Psaty, B
    Heckbert, S
    Wassertheil-Smoller, S
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (10): : 991 - 1004
  • [25] Estrogen plus progestin and colorectal cancer in postmenopausal women
    Grant, ECG
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23): : 2417 - 2418
  • [26] Effect of postmenopausal hormones on inflammation-sensitive proteins - The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
    Cushman, M
    Legault, C
    Barrett-Connor, E
    Stefanick, ML
    Kessler, C
    Judd, HL
    Sakkinen, PA
    Tracy, RP
    CIRCULATION, 1999, 100 (07) : 717 - 722
  • [27] CONTINUOUS ESTROGEN-PROGESTIN THERAPY IN POSTMENOPAUSAL WOMEN
    SALPETER, S
    WESTERN JOURNAL OF MEDICINE, 1989, 151 (05): : 542 - 543
  • [28] Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women
    Darling, GM
    Johns, JA
    McCloud, PI
    Davis, SR
    NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09): : 595 - 601
  • [29] Plasma homocysteine in women taking hormone replacement therapy: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
    Barnabei, VM
    Phillips, TM
    Hsia, J
    JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE, 1999, 8 (09): : 1167 - 1172
  • [30] Estrogen and estrogen–progestin replacement therapy and risk of postmenopausal breast cancer in Canada
    Victoria Kirsh
    Nancy Kreiger
    Cancer Causes & Control, 2002, 13 : 583 - 590